Part 11/13:
In April 2025, a new complication emerged: Sinovac’s longstanding auditor, Grant Thornton, resigned abruptly, citing issues with the company’s financial statements. The resignation raised serious concerns about the firm’s transparency and financial integrity, especially since Sinovac had failed to complete audits for the 2024 fiscal year and advised that financial reports from previous years should no longer be relied upon.
This development casts uncertainty over Sinovac’s future plans to reverse the trading halt and resume operations. Until the company secures a new auditor and addresses its financial reporting issues, its shares will remain locked, and the cash reserves will stay inaccessible.